Related Experiment Video
Updated: Aug 19, 2025
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Nano C60 Promotes Synaptic Distribution of Phosphorylated CaMKIIα and Improves Cognitive Function in APP/PS1
Wei Dai1, Mingxu Zhao1, Caiyun Chen1
1Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei 230000, China.
Abstract:
The wide disparity in outcomes of Alzheimer's disease (AD) treatment from preclinical to clinical studies suggests an urgent need for more effective therapeutic targets and approaches to treat AD. CaMKII is a potential target for AD therapy; however, conflicting reports on the relationship between CaMKII and AD suggest a lack of deeper understanding of the interaction between CaMKII and AD. In addition to the lack of effective therapeutic targets, pharmacokinetic limitations of neuroprotective drugs, such as low lipophilicity to cross blood brain barrier, need to be urgently addressed in the practice of AD therapy. In this study, we prepared a carbon-based nanoparticle, Nano C60, and demonstrated that Nano C60 treatment promoted the translocation of phosphorylated CaMKIIα from the cytoplasm to the synapse in Aβ42 oligomers-treated cells and APP/PS1 mice. As a result, Nano C60 administration significantly improved spatial learning and memory in APP/PS1 mice. Our study suggests that synaptic-activated CaMKII may be more important than total CaMKII in AD treatment and provides a new strategy for AD therapy.
Insights
This study introduces Nano C60, a nanoparticle that enhances synaptic CaMKII activity to improve memory and learning in Alzheimer's disease models. It offers a new therapeutic strategy targeting synaptic function.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) treatment outcomes vary widely, highlighting the need for novel therapeutic targets.
- Calcium/calmodulin-dependent protein kinase II (CaMKII) is a potential AD target, but its precise role remains unclear.
- Neuroprotective drugs face pharmacokinetic challenges, including poor blood-brain barrier penetration.
Purpose of the Study:
- To investigate the therapeutic potential of a novel carbon-based nanoparticle, Nano C60, for Alzheimer's disease.
- To explore the effect of Nano C60 on CaMKII activity and its implications for cognitive function in AD models.
Main Methods:
- Preparation of Nano C60, a carbon-based nanoparticle.
- Treatment of cells with Aβ42 oligomers and APP/PS1 mice with Nano C60.
- Assessment of phosphorylated CaMKIIα translocation and spatial learning/memory.
Main Results:
- Nano C60 promoted the translocation of phosphorylated CaMKIIα to synapses in vitro and in vivo.
- Nano C60 administration significantly improved spatial learning and memory in APP/PS1 mice.
- Synaptic CaMKII activation emerged as a critical factor in AD treatment.
Conclusions:
- Nano C60 represents a promising new strategy for Alzheimer's disease therapy.
- Targeting synaptic CaMKII activation may be more effective than targeting total CaMKII for AD treatment.
- Nano C60 demonstrates potential for overcoming pharmacokinetic limitations of neuroprotective drugs.
